Abstract
Ergot-derived dopamine receptor agonists are often used in the treatment of Parkinson's disease. Cardiac valvulopathy has been associated with the use of the dopamine agonists, pergolide and cabergoline, in Parkinson's disease. In this case report, we present a patient who had cabergoline-induced mitral regurgitation. Turkish Başlık: Kabergolinin Neden Olduğu Hızlı Gelişen Mitral Yetersizliği Anahtar Kelimeler: Dopamin agonistleri; Parkinson hastalığı; mitral yetmezliği Ergot türevi dopamin reseptör agonistleri Parkinson hastalığının tedavisinde sıklıkla kullanılmaktadır. Parkinson hastalığında kabergolin ve pergolid gibi dopamin agonistlerinin kullanımı kardiyak valvulopati ile ilişkilidir. Bu olgu takdiminde, kabergolinin neden olduğu mitral yetmezliği bulunan bir olgu sunulmaktadır.
References
- 1. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
- 2. Horvath J, Burkhard PR, Liaudat S, Lerch R, Stalder H. Severe valvular heart disease associated with the use of an ergot-derivative dopamine agonist in a patient with Parkinson’s disease. Mov Disord 2002;17(Suppl 5):S69(P185).
- 3. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
- 4. Pinero A, Marcos-Alberca P, Fortes J. Cabergolinerelated severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7.
- 5. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
- 6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
- 7. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinsonʼs disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179-83.
- 8. Botero M, Fuchs R, Paulus DA, Lind DS. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63. 9. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
- 10. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiacvalve regurgitation. N Engl J Med 2007;356:29-38.
- 11. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P, et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinsonʼs disease patients treated with cabergoline. J Neural Transm
Abstract
Ergot-derived dopamine receptor agonists are often used in the treatment of Parkinson's disease. Cardiac valvulopathy has been associated with the use of the dopamine agonists, pergolide and cabergoline, in Parkinson's disease. In this case report, we present a patient who had cabergoline-induced mitral regurgitation. Turkish Başlık: Kabergolinin Neden Olduğu Hızlı Gelişen Mitral Yetersizliği Anahtar Kelimeler: Dopamin agonistleri; Parkinson hastalığı; mitral yetmezliği Ergot türevi dopamin reseptör agonistleri Parkinson hastalığının tedavisinde sıklıkla kullanılmaktadır. Parkinson hastalığında kabergolin ve pergolid gibi dopamin agonistlerinin kullanımı kardiyak valvulopati ile ilişkilidir. Bu olgu takdiminde, kabergolinin neden olduğu mitral yetmezliği bulunan bir olgu sunulmaktadır.
References
- 1. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
- 2. Horvath J, Burkhard PR, Liaudat S, Lerch R, Stalder H. Severe valvular heart disease associated with the use of an ergot-derivative dopamine agonist in a patient with Parkinson’s disease. Mov Disord 2002;17(Suppl 5):S69(P185).
- 3. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
- 4. Pinero A, Marcos-Alberca P, Fortes J. Cabergolinerelated severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7.
- 5. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
- 6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
- 7. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinsonʼs disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179-83.
- 8. Botero M, Fuchs R, Paulus DA, Lind DS. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63. 9. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
- 10. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiacvalve regurgitation. N Engl J Med 2007;356:29-38.
- 11. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P, et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinsonʼs disease patients treated with cabergoline. J Neural Transm
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | March 1, 2008 |
| Published in Issue | Year 2008 Volume: 2008 Issue: 3 |